Ajanta Pharma Ltd.

₹3,459.8

106.2 (3.2%)

AJANTPHARM Share Price

Pharmaceuticals & Biotechnology

As on October 28, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 43,132.1 Cr

P/E Ratio40.92

Dividend Yield0.4 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	3,349.78	Bullish
10-DMA	3,329.54	Bullish
20-DMA	3,412.86	Bullish
50-DMA	3,500.91	Bearish
100-DMA	3,417.46	Bullish
200-DMA	3,158.58	Bullish

Historical Performance

1 Year

44.9%

3 Years

97%

5 Years

143%

10 Years

154.2%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	54,529	46,481	42,087	37,426	33,410
Total Expenditure	40,580	33,886	30,368	29,594	24,117
Other Income	1,721	945	846	986	1,157
Operating Profit	15,669	13,540	12,565	8,819	10,450
Interest	161	207	72	58	102
Depreciation	1,731	1,441	1,354	1,308	1,253
Profit Before Tax	13,777	11,892	11,139	7,452	9,095
Consolidated Net Profit	10,560	9,204	8,162	5,880	7,127
Adjusted EPS	85	74	65	47	56

Compounded Sales Growth

10 Years:25.8

5 Years:13.5

3 Years:7.8

TTM:3.2

Compounded Profit Growth

10 Years:20.5

5 Years:10.1

3 Years:12.4

TTM:2.8

Stock Price CAGR

10 Years:9.8

5 Years:19.6

3 Years:25.4

TTM:40.6

Return on Equity

10 Years:38.4

5 Years:55.6

3 Years:64.8

last year:84.5

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	251	251	253	253	172
Total Reserves	44,988	37,600	35,364	33,624	32,469
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	325	421	408	1,774	2,850
Other Current Liabilities	6,287	4,780	3,695	6,694	3,015
Short Term Borrowings	2,069	---	---	---	---
Total Liabilities	62,466	51,174	45,039	47,046	41,968
Capital Work in Progress	2,580	1,763	2,565	2,095	1,529
Long Term Loans & Advances	849	182	144	1,348	2,365
Currents Investments	5,598	4,387	3,300	5,103	1,219
Short Term Loans and Advances	4,970	3,782	1,323	894	851
Total Current Assets	40,066	31,186	27,221	28,252	22,645
Total Assets	62,466	51,174	45,039	47,046	41,968
Adjusted Book Value	362	303	283	269	255

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 40.92, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 25.4%, indicating sustained price appreciation.
The stock carries a low beta of 0.5, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹15669 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹54529 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1405337.3

No. of Shares: 406 (Approx)

Performance:40.5%

405337.3

NIFTY Performance: -12.9%

1 day Top Gainers